Previous 10 | Next 10 |
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York PR Newswire Live Audio Webcast to Begin at 8:00 a.m. Eastern Time SAN RAFAEL, Calif. ...
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th PR Newswire BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Deve...
BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire Citi's 18th Annual BioPharma Conference on September 6 at 3:30pm ET Morgan Stanley 21st Annual Global Healthcare Conference on September 11 at 10:00am ET Baird's 2023 G...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe PR Newswire First Person Treated in Germany ; Reimbursement Discussions on Track in France and Italy In the U.S., R...
2023-08-05 15:01:37 ET Summary BioMarin's 2Q23 revenue rose 12% YoY to $595 million, with adjusted EBITDA at $135 million. Revenues of the mucopolysaccharidosis drug portfolio decreased 6% YoY, but Voxzogo's quarterly sales were $113 million, up 29% QoQ. Voxzogo and ValRox rem...
2023-08-02 13:00:00 ET Summary We've compiled a list of July investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. Featured here are the investmen...
2023-07-31 20:14:08 ET Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Conference Call July 31, 2023, 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer - Chie...
2023-07-31 16:06:54 ET BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q2 Non-GAAP EPS of $0.54 beats by $0.07 . Revenue of $595.3M (+11.5% Y/Y) in-line. FY23 Total Revenues Guidance unchanged at $2,375M to $2,500M, vs. consensus of $2.44B. Non-GAAP Dil...
BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date PR Newswire VOXZOGO ® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased ...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...